Form 4: Neurocrine Biosciences Executive Exercises Options and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, exercised stock options and sold shares on July 1, 2024, according to a pre-arranged 10b5-1 trading plan.
Summary
- On July 1, 2024, Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, exercised non-qualified stock options to acquire 272 shares of common stock at a price of $79.02 per share.
- Simultaneously, Delaet sold 272 shares of common stock at $138.11 per share.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on November 29, 2023.
- Following these transactions, Delaet directly owns 7,507 shares of Neurocrine Biosciences common stock and holds options for 4,354 shares.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment about the company's prospects.
Future Outlook
The filing does not contain any specific forward-looking statements regarding the company's future performance or prospects.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's valuation and future prospects. The use of 10b5-1 plans allows insiders to sell shares while mitigating concerns about trading on non-public information.
Comparison to Industry Standards
- Executive compensation packages in the biotechnology industry often include stock options as a significant component.
- The vesting schedule of the options (48 equal monthly installments) is a standard practice.
- The use of Rule 10b5-1 trading plans is a common method for executives to manage their stock holdings while complying with insider trading regulations.
- Comparing the volume and frequency of insider transactions at Neurocrine Biosciences to those of its peers (e.g., Biogen, Vertex Pharmaceuticals) could provide a broader context for assessing the significance of these transactions.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders.
- Shareholders may be interested in insider trading activity as an indicator of management's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| November 29, 2023 | Date the Reporting Person adopted the Rule 10b5-1 trading plan |
| January 31, 2022 | Date the option was granted |
| February 28, 2022 | Vesting start date of the option in 48 equal monthly installments |
| July 1, 2024 | Date of the transaction (exercise of options and sale of shares) |
| July 2, 2024 | Date of the Form 4 filing |
| January 31, 2032 | Expiration date of the options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.